Type 2 diabetes mellitus and sequelae constitute a major health problem, affecting more than 29 million people in the US and almost 60 million in Europe[@b1]. Diabetes mellitus is the principal cause of end stage renal disease (ESRD) requiring renal replacement therapy[@b2][@b3]. It is hence important to identify patients at risk of developing diabetic nephropathy. Microalbuminuria is considered the first detectable sign of renal involvement in diabetes and used for screening of incipient diabetic nephropathy[@b4][@b5]. However, risk of progression to diabetic nephropathy as well as associated cardiovascular risk is considered a continuum, starting in the range of normal urinary albumin excretion[@b6][@b7]. More sensitive biomarkers are hence required to detect patients at risk at an earlier time point and improve efficacy of preventive strategies. Whereas in acute kidney injury, several biomarkers have been proposed for early risk stratification, there are no biomarkers identified for chronic kidney disease, especially for early detection of diabetic nephropathy.

Urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored receptor of urokinase and expressed on immune cells as well as on endothelial cells, fibroblasts and podocytes[@b8][@b9]. Its soluble form (suPAR) is formed by cleavage of the membrane-bound GPI anchor and is detectable in various extracellular compartments[@b8][@b10]. suPAR is a three domain protein with a molecular weight of 20--50 kD, depending on its degree of glycosylation[@b11]. uPAR/suPAR compounds are involved in inflammation and immune response[@b12] and elevated serum suPAR concentrations have been described in malignancies and infections[@b8].

As a first hallmark in nephrology, suPAR was described a circulating factor in focal segmental glomerulosclerosis (FSGS) in 2011[@b11]. Recently, Hayek and coworkers first described a predictive role of plasma suPAR for the development of chronic kidney disease (CKD) in a risk cohort of patients with cardiovascular disease[@b13]. This finding was especially pronounced in patients with normal renal function at baseline, strengthening the value of suPAR as an early risk indicator for the development of CKD.

As a marker of inflammation, suPAR has also been investigated in the context of metabolic syndrome and diabetes. Higher suPAR concentrations at baseline have been associated with incident type 2 diabetes in prospective analyses[@b14][@b15]. In manifest diabetes, suPAR was associated with diabetes-related complications in a cross-sectional analysis[@b16].

The link between suPAR, albuminuria and diabetes together with the finding of a predictive value for CKD intrigued us to assess the potential of suPAR in predicting onset of albumin excretion in patients at risk for type 2 diabetes. We hypothesized that suPAR is an earlier marker of incipient diabetic nephropathy than microalbuminuria.

Results
=======

We investigated two cohorts from the Tübingen University Hospital. The TULIP prospective cohort with subjects at increased risk of developing type 2 diabetes (*n* = 258) to address the question whether suPAR concentrations predict onset of microalbumiuria and the ICEPHA cross-sectional cohort, consisting of patients with manifest type 2 diabetes (*n* = 266), to confirm an association of suPAR and urinary albumin excretion at later stages of the disease. Respective baseline characteristics are given in [Table 1](#t1){ref-type="table"}.

Distribution of serum suPAR concentrations
------------------------------------------

In the TULIP cohort, baseline suPAR concentrations ranged from 946 pg/ml to 3701 pg/ml with a median of 2112 \[1871--2383\] pg/ml. In the ICEPHA cohort with manifest type 2 diabetes, suPAR concentrations were significantly higher with a median of 2974 \[2497--3482\] pg/ml (*p* \< 0.0001). Minimum concentration was 1080 pg/ml, maximum concentration 7306 pg/ml. Distribution of suPAR concentrations is shown in [Fig. 1](#f1){ref-type="fig"}.

Prospective analysis of suPAR concentrations and new-onset albuminuria
----------------------------------------------------------------------

In the TULIP cohort, subjects were followed-up for a median of 2.3 \[2.0--8.7\] years until first onset of microalbuminuria (defined as endpoint) or the last UACR measurement, if no microalbuminuria occured. There were 32 events of new-onset microalbuminuria (12.4%). Initial analysis of the cumulative hazard plot stratified for baseline suPAR below or above the median (2112 pg/ml) showed a separation of the plots after 8 years ([Fig. 2](#f2){ref-type="fig"}). Since the hazard related to baseline suPAR levels tended to increase over time (cf. [Supplementary Fig. S1](#S1){ref-type="supplementary-material"}), we performed a weighted Cox regression analysis. In the univariate model, baseline suPAR significantly associated with the incidence of new-onset microalbuminuria (e^ß^ = 1.0011 per pg/ml higher suPAR, *p* = 0.001). A significant interaction between time and baseline suPAR (e^ß^ = 1.0002 per year, *p* = 0.03) suggested that the effect increased over time. After adjustment for baseline eGFR, suPAR remained a significant predictor of new-onset microalbuminuria (*p* = 0.0003). This association was not abolished after further adjustment for baseline blood pressure (expressed as mean arterial pressure, MAP), glycemia (baseline HbA1c) and the use of angiotensin converting-enzyme inhibitors or angiotensin AT~1~-receptor antagonists (ARB) (for suPAR, *p* = 0.0002 in the model with all covariates). The estimated relative hazard for a given baseline suPAR level after adjustment for baseline eGFR, blood pressure, glycemia and nephroprotective medication is displayed in [Fig. 3](#f3){ref-type="fig"}. When comparing quartiles of suPAR, participants in the highest vs. lowest quartile of suPAR had a hazard ratio of 5.3 (CI: 1.1--25.2, *p* = 0.03) for new-onset microalbuminuria.

Characterization of subjects reaching the endpoint
--------------------------------------------------

Characteristics of subjects with new-onset microalbuminuria and those not reaching the endpoint during follow-up are given in [Table 2](#t2){ref-type="table"}. In subjects reaching the endpoint, median time to incident microalbuminuria was 3.1 years, ranging from 1.5 to 8.8 years. The proportion of females was significantly higher among subjects developing microalbuminuria (*p* = 0.04). Otherwise, there were no significant differences in anthropometrics. At end of follow-up, the number of subjects with prediabetes was higher in those developing microalbuminuria, compared to those who did not. In accordance, HbA1c was significantly higher in these subjects (*p* = 0.03). Median eGFR was comparable among subjects with and without new-onset microalbuminuria. Mean arterial blood pressure or the use of ACEI or ARB did not differ between groups.

Correlation of serum suPAR concentrations and albuminuria in manifest type 2 diabetes
-------------------------------------------------------------------------------------

In an independent cross-sectional cohort of patients with manifest type 2 diabetes (ICEPHA), suPAR concentrations significantly correlated with albuminuria (r^2^ = 0.08, *p* \< 0.0001). Higher suPAR levels were associated with an increase in albuminuria.

Discussion
==========

The main finding of the present investigation is that serum suPAR independently associates with new-onset microalbuminuria in subjects at increased risk for type 2 diabetes. This finding was persistent after adjustment for known risk factors for urinary albumin excretion. In an independent cohort with manifest type 2 diabetes, the association of suPAR and urinary albumin excretion was conserved at later stages of disease.

Microalbuminuria is considered the earliest detectable marker of diabetic nephropathy and state-of-the-art in screening for renal involvement in diabetes mellitus. Microalbuminuria is an independent risk factor for progression to proteinuria[@b17] and subsequent loss of renal function[@b4]. Moreover, the reduction of albumin excretion is a therapeutic target in diabetic nephropathy[@b18]. Current opinion considers the risk of developing diabetic nephropathy a continuum, starting at urinary albumin excretion still within the normal range[@b6][@b7]. Detection of incipient diabetic nephropathy at earlier time points is hence essential.

We now propose suPAR a candidate biomarker for this task. This concept is supported by an established pathophysiologic link between suPAR and podocyte integrity. suPAR binds to and activates β~3~-integrin, resulting in podocyte effacement and alteration of glomerular permselectivity[@b11]. Most data available is from patients with FSGS. In these patients, an association of suPAR and urinary albumin excretion has been shown and extracorporeal elimination of suPAR by plasmapheresis resulted in reduced β~3~-integrin activity and reduction of proteinuria[@b19]. In animal models of diabetic nephropathy, blockade of β~3~-integrin using monoclonal antibodies inhibits progression of albuminuria[@b20]. The effect of suPAR on podocyte function may be modulated by other pathways in a disease-specific manner. Unlike in FSGS, expression of sphingomyelinase-like phosphodiesterase 3b (SMPDL3b) is high in diabetic nephropathy, shifting suPAR mediated podocyte injury from a migratory (FSGS) to an apoptotic phenotype (diabetic nephropathy)[@b21]. Both will result in albuminuria. Clinically, an association of suPAR and urinary albumin excretion in diabetes has been shown in two cross-sectional analyses[@b16][@b22]. suPAR may hence mediate podocyte dysfunction and the onset of microalbuminuria in diabetic nephropathy.

A first indicator of a predictive role for suPAR in CKD is derived from the work of Hayek and coworkers who recently demonstrated a longitudinal association of baseline suPAR levels with a decline in eGFR and incident CKD in a cohort of patients with cardiovascular disease[@b13]. We now confirm a predictive role of suPAR in kidney disease in a different clinical setting in patients at increased risk of type 2 diabetes. In this cohort, suPAR predicted the onset of microalbuminuria, as the first clinical sign of renal involvement and clearly upstream of CKD and a decline in GFR. Importantly, this would allow the identification of patients at risk for diabetic nephropathy and CKD years in advance.

In defining the role of suPAR in kidney disease, discerning interactions between suPAR, albuminuria and decline in kidney function is key to gain insight into underlying pathomechanisms and to answer the question, whether suPAR merely associates with renal involvement in longitudinal observations (biomarker) or by itself is a driving force for a decline in renal function (progression factor). Our data now confirm the value of suPAR as a biomarker of kidney disease. Whether suPAR-mediated podocyte injury and albuminuria constitute a potential pathophysiologic link to CKD remains to be addressed in further studies.

As a biomarker, suPAR concentrations are affected by kidney function. With a molecular weight of 20--50 kD, suPAR is subject to glomerular filtration, and a number of investigations demonstrate an inverse relationship between suPAR and eGFR[@b22][@b23][@b24]. In our data, the association of suPAR with incident microalbuminuria was independent from baseline eGFR.

Only one of the subjects with new-onset microalbuminuria progressed to manifest diabetes throughout follow-up. So are we in fact looking at incipient diabetic nephropathy in our cohort? Renal involvement in diabetes has been shown prior to manifest disease in patients with prediabetes[@b25] and in normoglycemic individuals with insulin resistance[@b26]. Furthermore, triggering factors other than glycemia have been discussed for end-organ manifestations in diabetes[@b27][@b28]. In our carefully phenoptyped cohort, glycated hemoglobin levels were significantly higher and more subjects showed prediabetes among those developing microalbuminuria than in subjects not reaching the endpoint. Apart from this, no differences in other factors affecting urinary albumin excretion were observed. Taken together, these findings support the notion, that new-onset microalbuminuria in fact reflects incipient diabetic nephropathy in our prospective cohort.

Some limitations do apply to our data. The size of the cohorts is relatively small, albeit homogenous and, as for the TULIP cohort, one of the largest at-risk cohorts with long-term follow-up in the field of type 2 diabetes. Also, the number of subjects reaching an endpoint is small, in part owing to controlled lifestyle intervention. On the other hand, our conclusions are strengthened by a number of aspects: We investigate two carefully defined cohorts, applying the same methodology including urinalysis at different stages of the disease. By doing so, we demonstrate suPAR to be an independent predictor for the onset of microalbuminuria as a key indicator and progression factor of diabetic nephropathy and to consistently correlate to the magnitude of urinary albumin excretion in manifest disease. This not only underscores the relevance of this finding but also allows to hypothesize a potential pathophysiologic link between suPAR, urinary albumin excretion and progression to CKD in diabetic nephropathy, which has to be addressed in future trials. Importantly, the fact that we investigated an at-risk cohort, in which structured lifestyle intervention was performed to reduce the risk of progression, implies that the impact could even be stronger in an everyday clinical setting. Lastly, variance of baseline suPAR levels in the TULIP cohort is small. This reflects the homogeneity of an at-risk cohort for a disease. Most published data have evaluated suPAR in patients with manifest disease, with variable severity and comorbidity, or at increased risk of developing an associated complication, displaying higher variance. In line, our second cohort with manifest type 2 diabetes showed higher absolute levels and variance of suPAR than TULIP.

In conclusion, we for the first time demonstrate that suPAR associates with the onset of microalbuminuria in patients at risk for type 2 diabetes, preceding known markers of renal involvement by several years. An earlier identification of patients at risk for diabetic nephropathy may allow for more effective prevention and improve patient prognosis.

Methods
=======

Study population
----------------

Participants were studied from two cohorts at the Tübingen University Hospital. The prospective cohort is the Tübingen Lifestyle Intervention Program (TULIP) study. The study was designed to prospectively assess the effect of lifestyle intervention on metabolic phenotype in subjects at increased risk of type 2 diabetes. TULIP included individuals from 2003--2005 with subjects recruited by newspaper invitation or personal recommendation. Inclusion criteria were a family history of type 2 diabetes, a body mass index (BMI) \> 27 kg/m^2^, impaired glucose tolerance or a history of gestational diabetes. The TULIP study was approved by the Institutional Ethics Committee of the Medical Faculty of Tübingen (422/2002) and conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all subjects prior to inclusion. Lifestyle modification consisted of guided dietary modification (intake of less than 30% of total calories as fat, reduction in saturated fatty acids and increased amount of fibers) as well as increased physical activity (3 h of moderate physical activity per week). Participants had planned follow-up visits at the end of lifestyle intervention at 9 months and after 24 months, and were subsequently invited for long-term follow-up. Visits included an extended oral glucose tolerance test to assess metabolic parameters, as well as routine laboratory and urinalysis.

In the TULIP study, fasting venous blood samples were obtained on each occasion and serum and plasma stored at −80 °C. suPAR was measured at baseline examination prior to lifestyle intervention. Urinary albumin-to-creatinine-ratios (UACR) were determined from freshly voided spot urine samples. Samples were collected before the oral glucose tolerance test on each occasion. Incident microalbuminuria was defined as occurrence of UACR ≥30 mg/g creatinine, given this finding was not present at a prior examination. Samples with dipstick leukocyturia were excluded from the analyses as were participants with C-reactive protein levels over 0.5 mg/dl. All participants included in the analysis had a UCAR below 30 mg/g at baseline.

The cross-sectional cohort is from the ICEPHA study, conducted by the Interfaculty Centre for Pharmacogenomics and Pharma Research (ICEPHA) of Tübingen and Stuttgart. The study was planned to establish individualized therapy for patients with type 2 diabetes and is conducted as a registry to assess clinical phenotypes and laboratory parameters related to type 2 diabetes. The study included from 2011--2012 and recruited via regular visit in our diabetes outpatient clinic, without exclusion criteria. Inclusion criterion was manifest type 2 diabetes. The trial was approved by the Institutional Ethics Committee of the Medical Faculty of Tübingen (343/2010BO2) and conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all patients prior to inclusion in the trial. suPAR was measured at baseline together with routine laboratory including urinalysis.

In the present analysis, we assessed the association of baseline serum suPAR levels and (i) new-onset microalbuminuria as endpoint in long-term follow-up of the TULIP prospective cohort and (ii) the magnitude of urinary albumin excretion in the ICEPHA cross-sectional cohort.

Analytical measurements and calculations
----------------------------------------

Serum suPAR concentrations were measured using the Human uPAR Quantikine ELISA kit (R&D Systems, Wiesbaden, Germany) according to the manufacturers instruction. The minimal detectable concentration of suPAR is 33 pg/ml; the inter-assay variation is given as 5.1%, the intra-assay variation as 4.1%. Urinary albumin concentration was measured nephelometrically (BN ProSpec Nephelometer, Siemens Healthcare Diagnostics, Eschborn, Germany) and creatinine quantified enzymatically (ADVIA 1800 Clinical Chemistry System, Siemens Healthcare Diagnostics, Eschborn, Germany). Plasma glucose was measured on the ADVIA 1800 clinical chemistry analyzer (hexokinase method), HbA1c was measured by high performance liquid chromatography (Tosoh G8 HPLC Analyzer, Tokyo, Japan).

UACR was calculated from urinary albumin and creatinine concentrations. For calculation of eGFR, the CKD-EPI equation was used, which takes into account age and gender[@b29].

Statistical analysis
--------------------

Variables are given as median and interquartile range. Distribution was tested with histograms and Shapiro-Wilk test. Groups were compared using Wilcoxon test for continuous variables and Fisher's exact test for categorical variables.

To test the hypothesis if baseline suPAR levels predict new-onset microalbuminuria, we intended to use a proportional hazards (Cox) model. Since the effect of baseline suPAR levels tended to increase over time (cf. [Supplementary Fig. S1](#S1){ref-type="supplementary-material"}), the proportionality assumption of the original Cox model was violated. To overcome this limitation, we applied the weighted Cox regression method proposed by Schemper, Wakounig and Heinze[@b30]. Weighted Cox regression provides unbiased average hazard ratio estimates also in case of non-proportional hazards.

To test the correlation of suPAR with albuminuria in manifest type 2 diabetes, univariate linear regression analysis was used. Non-normally distributed parameters were log transformed to approximate normal distribution prior to analysis.

Results with values of p \< 0.05 were considered statistically significant. Analyses were performed using JMP 11.0 (SAS Institute, Cary, NC) and R version 3.2.2 (R foundation for statistical computing, Vienna, Austria).
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Cumulative hazard of incident microalbuminuria in longitudinal follow-up of the TULIP prospective cohort.](srep40627-f2){#f2}

![Relative hazard of baseline suPAR for incident microalbuminuria.\
Non-linear relative hazard function plot (effect estimates from the weighted cox regression model) showing the modeled association between baseline suPAR concentrations and incident microalbuminuria in the TULIP prospective cohort.](srep40627-f3){#f3}

###### Baseline characteristics of cohorts.

                                                   TULIP prospective cohort   ICEPHA cross-sectional cohort
  ----------------------------------------------- -------------------------- -------------------------------
  *n*                                                        258                           266
  gender (m/f)                                             110/148                       152/114
  age (yrs)                                             47 \[39--54\]                 64 \[56--71\]
  BMI\* (kg/m^2^)                                    29.0 \[26.6--31.9\]           33.3 \[29.5--37.9\]
  yrs since dx of diabetes                                   n.a.                     9.5 \[5--16\]
  FPG^†^ (mmol/l)                                      5.2 \[4.8--5.6\]             8.6 \[7.2--10.6\]
  HbA1c^‡^ (%)                                         5.6 \[5.3--5.9\]             7.6 \[6.9--9.2\]
  plasma creatinine (μmol/l)                         88.4 \[79.6--88.4\]           70.7 \[61.9--88.4\]
  eGFR CKD-EPI^§^ (ml/min/1.73 m^2^)                    81 \[72--93\]                 90 \[66--99\]
  UACR^II^ (mg/g Crea)                                    6 \[4--9\]                  16 \[8--61\]
  MAP^¶^ (mmHg)                                         90 \[83--98\]               105 \[100--110\]
  ACEI^\#^ or ARB\*\* use (*n*) \[y/n/unknown\]            14/244/0                     200/41/25
  serum suPAR concentrations (pg/ml)                 2112 \[1871--2383\]           2974 \[2497--3482\]

Date given as median \[interquartile range\]; n.a.: not applicable.

\*Body mass index, ^†^fasting plasma glucose, ^‡^glycated hemoglobin A1c, ^§^estimated glomerular filtration rate according to CKD-EPI formula[@b29], ^II^urinary albumin-to-creatinine ratio, ^¶^mean arterial blood pressure, ^\#^angiotensin converting enzyme inhibitor, \*\*angiotensin AT~1~-receptor antagonist.

###### Characteristics of subjects reaching the endpoint of new-onset microalbuminuria or not; TULIP prospective cohort.

                                                Baseline                 *p*           End of follow-up           *p*                                
  --------------------------------------- --------------------- --------------------- ------------------ --------------------- --------------------- ---------------
  *n*                                              32                    226                                      32                    226                  
  gender (m/f)                                    8/24                 102/124                                   8/24                 102/124          **0.04\***
  duration of follow-up (yrs.)                                                                             3.1 \[1.5--8.8\]      2.3 \[2.0--8.7\]         0.82
  age (yrs)                                   50 \[42--56\]         47 \[39--54\]            0.26            57 \[47--61\]         52 \[43--60\]          0.16
  BMI\* (kg/m^2^)                          28.9 \[25.8--32.2\]   29.0 \[26.7--31.9\]         0.95         28.7 \[25.1--31.7\]   29.0 \[26.2--32.2\]       0.57
  FPG^†^ (mmol/l)                           5.4 \[5.1--5.7\]      5.1 \[4.8--5.6\]           0.11          5.4 \[5.2--5.9\]      5.3 \[4.9--5.6\]         0.12
  HbA1c^‡^ (%)                              5.6 \[5.3--6.1\]      5.6 \[5.3--5.9\]           0.22          5.7 \[5.5--6.1\]      5.6 \[5.3--5.9\]      **0.03\***
  prediabetes^§^ (*n*)                             17                    141                 0.34                 25                    138               0.08
  eGFR CKD-EPI^II^ (ml/min/1.73 m^2^)         84 \[69--99\]         81 \[72--92\]            0.61           95 \[90--102\]        94 \[82--104\]          0.45
  UACR^¶^ (mg/g Crea)                             \<30                  \<30                                 39 \[34--75\]          8 \[5--14\]       **\<0.001\***
  MAP^\#^ (mmHg)                             97 \[86--101\]         90 \[83--98\]            0.08           100 \[87--108\]       95 \[89--103\]          0.24
  ACEI\*\* or ARB^††^ use (*n*) \[y/n\]           3/32                 11/226                0.39                3/32                 11/226              0.39

Date are given as median \[interquartile range\]. *p* values among groups at baseline or end of follow-up, respectively.

\*Body mass index, ^†^fasting plasma glucose, ^‡^glycated hemoglobin A1c, ^§^according to American Diabetes Association (ADA) criteria, ^II^estimated glomerular filtration rate according to CKD-EPI formula[@b29], ^¶^urinary albumin-to-creatinine ratio, ^\#^mean arterial blood pressure, \*\*angiotensin converting enzyme inhibitor, ^††^angiotensin AT~1~-receptor antagonist.
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